The story of Viagra presents a complex picture for investors. While the initial release generated significant returns, the end of its intellectual property protection opened the avenue to generic versions, dramatically diminishing revenue. This creates a unique risk for drug manufacturers relying on comparable blockbuster medications, suggesting th

The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in sales , its patent expiration created a deluge of knock-off medications, significantly impacting its position . While certain businesses may attempt to capitalize on related treatments , the current